Cortisone Shots - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cortisone shots market is projected to be USD 1.48 billion in 2025, USD 1.54 billion in 2026, and reach USD 1.99 billion by 2031, growing at a CAGR of 5.23% from 2026 to 2031. This report is Segmented by Product Type (Articular or Joint Injections, Epidural Steroid Injection, Trigger Point Injection), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Tendinitis, Allergic Reaction), End-User (Hospitals, Clinics, Sport Medicine Centers, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts Provided in Terms of Value (USD).

Global Cortisone Shots Market Trends and Insights

Rising Arthritis and Joint Disorder Burden

The cortisone shots market is being lifted by a disease burden that is expanding across osteoarthritis, rheumatoid arthritis, and other inflammatory joint conditions at the same time. Osteoarthritis affected more than 607 million people worldwide in 2021, and the older adult case count rose 148.7% between 1990 and 2021, which points to a very large and persistent patient pool for symptom relieving injections. Rheumatoid arthritis recorded 488,269 new incident cases globally in 2021, and its incidence trend continued to rise, which matters because these patients often require localized flare control even when disease modifying medicines are already in use. The cortisone shots market is also seeing a shift in the case mix, because faster growth in conditions such as psoriatic arthritis increases the use of injections as short duration support during treatment changes rather than only as a recurring maintenance option. That pattern raises treatment intensity for many diagnosed patients and helps the cortisone shots market hold value even in settings where prevalence growth itself is no longer moving as quickly.

Aging Population and Degenerative Joint Disease Incidence

The cortisone shots market is also supported by population aging, because older adults account for a large share of degenerative joint disease and are more likely to seek non surgical symptom relief. The World Health Organization states that musculoskeletal conditions remain the leading global cause of years lived with disability, with 149 million YLDs and 17% of all YLDs worldwide, which shows the depth of the clinical burden feeding procedure demand. The World Health Organization also states that 73% of people living with osteoarthritis are older than 55, and women carry a higher burden, which supports sustained treatment need in long living populations with recurrent pain and mobility limits. The cortisone shots market benefits from the fact that aging is happening across Japan, Germany, Italy, South Korea, China, and the United States within the same broad period, which creates demand growth across several large healthcare systems rather than in only one region. In middle income settings where surgery remains less affordable, the cortisone shots market gains further support because injections often become the most accessible specialist intervention available.

Injection Frequency Limits Due to Cartilage and Tendon Safety Concerns

The cortisone shots market faces an important limit because safety concerns reduce how often some patients can receive repeat injections. A 2 year double blind randomized trial cited in the 2025 ASRA and AAPM guideline found that triamcinolone acetonide 40 mg given every 12 weeks in knee osteoarthritis caused greater cartilage volume loss than saline without a matching improvement in pain benefit. These findings matter because they push physicians toward the lowest effective dose and longer intervals, which directly lowers the number of procedures a single patient may receive over time. The cortisone shots market therefore cannot rely on unlimited repeat use within existing patient pools, even when demand from new patients continues to rise. This is why growth increasingly depends on better patient selection, improved delivery systems, and the movement of injections toward more targeted episodic use.

Other drivers and restraints analyzed in the detailed report include:

• Preference for Non-Surgical Pain Management
• Expansion of Sports Medicine and Outpatient Injection Pathways
• Reimbursement Scrutiny for Repeated Injections

Segment Analysis

Articular or joint injections held 46.44% of segment revenue in 2025, which made them the largest product type in the cortisone shots market and confirmed the central role of direct intra articular delivery across knee, shoulder, hip, and ankle care. Their lead reflects long standing physician comfort with peripheral joint injection protocols in rheumatology and orthopedics, where localized symptom relief remains an important part of treatment planning for degenerative and inflammatory conditions. Within the broader cortisone shots industry, this segment also benefits from the wide anatomical range of treatable joints and from the steady flow of patients who are not ready for surgery or need temporary relief while other therapies are being adjusted.

Epidural steroid injections are projected to grow at a 5.66% CAGR through 2031, which makes them the fastest advancing product type in the cortisone shots market size by growth rate. Research published in the Journal of Controlled Release in 2026 described long acting triamcinolone acetonide prodrug microcrystals for sustained intra articular treatment, which signals broader formulation progress that may influence spinal delivery development as well. As more controlled release technologies move through validation, product differentiation in the cortisone shots market is likely to extend beyond simple molecule availability and toward duration, delivery profile, and billing support.

Complete Report Scope:

• By Product Type
  • Articular or Joint Injections
  • Epidural Steroid Injection
  • Trigger Point Injection
• By Indication
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Tendinitis
  • Allergic Reaction
• By End-User
  • Hospitals
  • Clinics
  • Sport Medicine Centers
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 47.15% of global revenue in 2025, which made it the largest regional contributor in the cortisone shots market and kept it in the lead in 2026. The region benefits from high musculoskeletal disease prevalence, dense specialist networks, advanced imaging capacity, and reimbursement structures that support injectable procedures in both hospital and outpatient settings. The United States accounts for most regional revenue because orthopedic and rheumatology care density remains high, and because bundled coding frameworks support routine use of image guided injections in appropriate cases. Mexico is the fastest growing country within North America, supported by wider access to private urban clinics that serve a working age population with a high musculoskeletal injury burden.

Europe held the second largest regional position in the cortisone shots market, with Germany, the United Kingdom, France, Italy, and Spain forming the core revenue base. Germany supports uptake through strong specialist care access, while the United Kingdom applies tighter evidence-based controls that limit publicly funded repeat treatment and shape procedure frequency. Spain and Italy are seeing broader use in sport medicine and private clinic settings, while their aging populations and hospital centered specialist networks continue to support procedure demand. Eastern Europe also presents room for expansion as specialist access improves and healthcare spending rises across markets such as Poland and the Czech Republic.

Asia-Pacific is projected to grow at a 7.61% CAGR through 2031, which makes it the fastest growing regional part of the cortisone shots market size and reflects both aging and access expansion. Japan remains central because osteoarthritis prevalence is high and the national insurance system supports corticosteroid injections in rheumatology and orthopedic practice, which helps preserve steady treatment volume. China is also expanding quickly as private musculoskeletal clinics and sport medicine centers grow in major cities, and as injections remain a more accessible option than surgery for many working age patients with degenerative joint disease. India, Australia, and urban Southeast Asia add further growth through better specialist access and rising outpatient procedure adoption. South America, the Middle East, and Africa remain smaller in current value, yet Brazil and Gulf Cooperation Council countries offer stronger potential than peers because private orthopedic capacity and health system investment are rising, while South Africa and Argentina continue to face financing and economic constraints that slow near term uptake.

List of Companies Covered in this Report:

• Abbvie
• Amneal Pharmaceuticals
• Anika Therapeutics
• Bayer
• Bioventus Inc.
• Bristol-Myers Squibb
• Dr. Reddy’s Laboratories
• Ferring Pharmaceuticals
• Fresenius
• Hikma Pharmaceuticals
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Sandoz Group AG
• Sanofi
• Seikagaku
• Smiths Group
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support